These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10602739)

  • 1. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis.
    Greenberg RN; Newman MT; Shariaty S; Pectol RW
    Antimicrob Agents Chemother; 2000 Jan; 44(1):164-6. PubMed ID: 10602739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.
    Klimberg IW; Cox CE; Fowler CL; King W; Kim SS; Callery-D'Amico S
    Urology; 1998 Apr; 51(4):610-5. PubMed ID: 9586615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.
    Richard GA; Klimberg IN; Fowler CL; Callery-D'Amico S; Kim SS
    Urology; 1998 Jul; 52(1):51-5. PubMed ID: 9671870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ciprofloxacin, ofloxacin, and lomefloxacin as alternatives to intravenous antimicrobial therapy.
    Belliveau P; Nightingale CH; Quintiliani R; Crowe H; Gousee G
    Conn Med; 1993 Aug; 57(8):539-45. PubMed ID: 8243083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
    Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
    Antimicrob Agents Chemother; 1997 May; 41(5):1193-5. PubMed ID: 9145900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
    Fong IW
    Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
    Kaye KS; Kanafani ZA; Dodds AE; Engemann JJ; Weber SG; Carmeli Y
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2192-6. PubMed ID: 16723582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Levofloxacin (Tavanic) in the treatment of corneal ulcers].
    Maĭchuk IuF
    Antibiot Khimioter; 2003; 48(6):16-9. PubMed ID: 14558414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up.
    Galanakis N; Giamarellou H; Moussas T; Dounis E
    J Antimicrob Chemother; 1997 Feb; 39(2):241-6. PubMed ID: 9069546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lomefloxacin is an effective treatment of experimental bacterial keratitis.
    Kowalski RP; Romanowski EG; Yates KA; Gordon YJ
    Cornea; 2001 Apr; 20(3):306-8. PubMed ID: 11322421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections.
    Cox CE
    Am J Med; 1992 Apr; 92(4A):82S-86S. PubMed ID: 1316077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study.
    Pisani E; Bartoletti R; Trinchieri A; Rizzo M
    J Chemother; 1996 Jun; 8(3):210-3. PubMed ID: 8808718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
    Bundrick W; Heron SP; Ray P; Schiff WM; Tennenberg AM; Wiesinger BA; Wright PA; Wu SC; Zadeikis N; Kahn JB
    Urology; 2003 Sep; 62(3):537-41. PubMed ID: 12946763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
    Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of lomefloxacin (SC-47111) and other quinolones.
    Sun ZM; Maskell JP; Sehgal SC; Williams JD
    Infection; 1989; 17(3):165-7. PubMed ID: 2737760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.